Archer Pharmaceuticals Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.51M
- Investors
-
2
Archer Pharmaceuticals General Information
Description
Operator of a pharmaceutical company specializing in drug discovery for Alzheimer's disease and other dementias. The company's research is committed to identifying convenient, safe, orally administered medications to slow or prevent the progression of Alzheimer's disease, helping the medical industry to reduce the global burden of the disease and the level of care required by patients.
Contact Information
Website
www.archerpharmaceuticals.comCorporate Office
- 2040 Whitfield Avenue
- Sarasota, FL 34243
- United States
Corporate Office
- 2040 Whitfield Avenue
- Sarasota, FL 34243
- United States
Archer Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 01-May-2020 | $1.51M | Completed | Clinical Trials - General | ||
| 3. Grant | 30-Sep-2018 | Completed | Clinical Trials - General | |||
| 2. Grant | 01-Jan-2011 | $150K | $2.7M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 08-Dec-2008 | $2.7M | $2.7M | Completed | Startup |
Archer Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Archer Pharmaceuticals Patents
Archer Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20090092667-A1 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer | Active | 05-Oct-2007 | ||
| US-8236346-B2 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer | Inactive | 05-Oct-2007 | ||
| US-20080058330-A1 | Brain disorders; alzheimer's disease | Inactive | 06-Jul-2006 | ||
| US-8067372-B2 | Modulation of angiogenesis by a-beta peptide fragments | Active | 10-Nov-2005 | ||
| US-20080031954-A1 | Modulation of angiogenesis by a-beta peptide fragments | Active | 10-Nov-2005 | C07K14/4711 |
Archer Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Archer Pharmaceuticals Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| The National Institute on Aging (NIA) | Government |
Archer Pharmaceuticals FAQs
-
When was Archer Pharmaceuticals founded?
Archer Pharmaceuticals was founded in 2008.
-
Where is Archer Pharmaceuticals headquartered?
Archer Pharmaceuticals is headquartered in Sarasota, FL.
-
What is the size of Archer Pharmaceuticals?
Archer Pharmaceuticals has 11 total employees.
-
What industry is Archer Pharmaceuticals in?
Archer Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Archer Pharmaceuticals a private or public company?
Archer Pharmaceuticals is a Private company.
-
What is Archer Pharmaceuticals’s current revenue?
The current revenue for Archer Pharmaceuticals is .
-
How much funding has Archer Pharmaceuticals raised over time?
Archer Pharmaceuticals has raised $2.7M.
-
Who are Archer Pharmaceuticals’s investors?
National Institutes of Health and The National Institute on Aging (NIA) have invested in Archer Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
